Overview

Study to Evaluate the Safety and Efficacy of PAZ320 in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the effect that PAZ320 has on post-prandial glucose excursions measured via continuous glucose monitoring and its adverse effect profile in humans.
Phase:
Phase 2
Details
Lead Sponsor:
Boston Therapeutics
Treatments:
PAZ320